Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today ...

Dyadic International, Inc. (NASDAQ:DYAI) Q3 2024 Earnings Call Transcript November 16, 2024 Operator: Operator: Good evening, and welcome to Dyadic International Q3 2024 Conference Call.

Dyadic International (DYAI) announced that it has been awarded a $3M grant from the Gates Foundation for the cell line development of monoclonal antibodies targeting respiratory syncytial virus ...

Dyadic International Inc. ( (DYAI)) has released its Q3 earnings. Here is a breakdown of the information Dyadic International Inc. presented to its investors. Dyadic International, Inc. is a ...

“We believe our third quarter achievements underscore Dyadic’s commitment to leveraging our proprietary Dapibus™ and C1 microbial protein production platforms to drive immediate and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Based on the one-year price targets offered by 1 analyst, the average target price for Dyadic International Inc (NASDAQ:DYAI) is $6.00 with a high estimate of $6.00 and a low estimate of $6.00.

Dyadic International Inc (NASDAQ:DYAI) reported a significant increase in revenue for Q3 2024, reaching approximately $1,958,000 compared to $397,000 for the same period a year ago. The company has ...

India Funds Affordable COVID-19 Vaccine Candidate Using Dyadic's Platform ...

Good evening, and welcome to Dyadic International Q3 2024 Conference Call. Currently, all participants are in a listen-only mode. Following management’s prepared remarks, there will be a brief ...